Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 10, 2015, 81 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $2,123.51 to $171,339,525.00.

Highlighted Stocks Traded by Insiders:

Salesforce.com (CRM) - FREE Research Report

Norton Burke F, who is EVP and Chief Legal Officer at Salesforce.com, sold 5,000 shares at $58.69 on Feb. 10, 2015. Following this transaction, the EVP and Chief Legal Officer owned 42,701 shares meaning that the stake was reduced by 10.48% with the 5,000-share transaction.

The shares most recently traded at $58.79, up $0.10, or 0.17% since the insider transaction. Historical insider transactions for Salesforce.com go as follows:

  • 4-Week # shares sold: 207,900
  • 12-Week # shares sold: 663,865
  • 24-Week # shares sold: 1.7 million

The average volume for Salesforce.com has been 4.8 million shares per day over the past 30 days. Salesforce.com has a market cap of $36.6 billion and is part of the technology sector and computer software & services industry. Shares are down 0.88% year-to-date as of the close of trading on Tuesday.

salesforce.com, inc. provides enterprise cloud computing solutions to various businesses and industries worldwide. Currently, there are 24 analysts who rate Salesforce.com a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRM - FREE

TheStreet Quant Ratings

rates Salesforce.com as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and a generally disappointing performance in the stock itself. Get the full

TheStreet Recommends

Salesforce.com Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Hydrogenics (HYGS) - FREE Research Report

CommScope, Inc. of North Carolina, who is 10% Owner at Hydrogenics, sold 13,589 shares at $14.36 on Feb. 10, 2015. Following this transaction, the 10% Owner owned 1.5 million shares meaning that the stake was reduced by 0.91% with the 13,589-share transaction.

The shares most recently traded at $14.55, up $0.19, or 1.29% since the insider transaction. Historical insider transactions for Hydrogenics go as follows:

  • 4-Week # shares sold: 39,843
  • 12-Week # shares sold: 39,843
  • 24-Week # shares sold: 132,943

The average volume for Hydrogenics has been 97,100 shares per day over the past 30 days. Hydrogenics has a market cap of $141.8 million and is part of the industrial goods sector and industrial industry. Shares are up 5.72% year-to-date as of the close of trading on Tuesday.

Hydrogenics Corporation, together with its subsidiaries, designs, develops, and manufactures hydrogen generation products based on water electrolysis technology; and fuel cell products based on proton exchange membrane technology. Currently, there are 2 analysts who rate Hydrogenics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HYGS - FREE

TheStreet Quant Ratings

rates Hydrogenics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Hydrogenics Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Boston Scientific (BSX) - FREE Research Report

Pierce David A, who is SVP and President, Endoscopy at Boston Scientific, sold 5,000 shares at $14.66 on Feb. 10, 2015. Following this transaction, the SVP and President, Endoscopy owned 28,161 shares meaning that the stake was reduced by 15.08% with the 5,000-share transaction.

Ballinger Kevin J., who is SVP & Pres, Interven Cardio at Boston Scientific, sold 21,408 shares at $15.06 on Feb. 10, 2015. Following this transaction, the SVP & Pres, Interven Cardio owned 28,440 shares meaning that the stake was reduced by 42.95% with the 21,408-share transaction.

The shares most recently traded at $14.76, down $0.30, or 2.02% since the insider transaction. Historical insider transactions for Boston Scientific go as follows:

  • 4-Week # shares bought: 11,700
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 11,700
  • 12-Week # shares sold: 100,954
  • 24-Week # shares bought: 21,700
  • 24-Week # shares sold: 154,951

The average volume for Boston Scientific has been 12.7 million shares per day over the past 30 days. Boston Scientific has a market cap of $19.2 billion and is part of the health care sector and health services industry. Shares are up 11.09% year-to-date as of the close of trading on Tuesday.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. The company has a P/E ratio of 72.2. Currently, there are 13 analysts who rate Boston Scientific a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BSX - FREE

TheStreet Quant Ratings

rates Boston Scientific as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Boston Scientific Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null